Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2017

View Archived Issues

New STRN-ALK fusion gene-driven PDTC mouse model developed

NewLink Genetics initiates phase I study of NLG-802

Boehringer Ingelheim begins VOLTAIRE-X interchangeability study of adalimumab biosimilar

Mutant EGFR and/or HER2 inhibitors presented by Ancureall Biomedical Technology

ITGA7 gene variant discovered to influence risk of proteinopathies

European Commission approves Vosevi, extends Harvoni indication

Bristol-Myers Squibb updates clinical and regulatory progress of second quarter 2017

Roche advances pipeline in second quarter 2017

MHCSZ-123 antibody offers strong antithrombotic effects by inhibition of collagen binding

Sumitomo Dainippon offers overview of first quarter of fiscal 2017

Mitsubishi Tanabe initiates phase IIa trial of MT-8554 in painful diabetic peripheral neuropathy

Evotec to acquire Aptuit

Hua Medicine patents mGlu5 receptor antagonists

Sophia Bioscience divulges histone deacetylase inhibitors

Raziel intiates phase IIa study of RZL-012 to treat obesity by inducing thermogenesis

Guangzhou Henovcom Bioscience discovers FXR agonists

Adenosine A3 receptor antagonists identified at Handok

Otsuka files for Japanese approval of ASC-01 for major depressive disorder

Sperovie Biosciences patents PDE4B and/or TNF-alpha release inhibitors

Kyowa Hakko Kirin updates U.S. and E.U. regulatory progress of burosumab

European Commission approves AbbVie's Maviret for chronic HCV genotypes 1-6

FDA advisory committee votes in favor of Heplisav-B

FDA approves Abilify Maintena for maintenance treatment of bipolar I disorder

KPM-2 shows promise in cancer and neurodegenerative disorders

CytRx and NantCell sign strategic license for aldoxorubicin

FDA grants breakthrough therapy designation to Imfinzi for locally advanced unresectable NSCLC

Tenax reviews options after FDA requests additional clinical trial for levosimendan

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...